Replies to post #192414 on Biotech Values

[ciotera]

RE: Venetoclax+R

12% CR is too low and 50% relapse after 12m is too high to risk taking a patient off therapy, esp. if they are 17p del. Good thing they bought Imbruvica so that they don't have to compete against it (at least in the US).